New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
06:41 EDTAKERAkers Biosciences signs distribution agreement for infectious disease tests
Akers Biosciences announces a distribution agreement with Thirty Six Strategies General Trading, for the sale of the Company's PIFA PLUSS Infectious Disease Rapid Assay product line and Tri-Cholesterol "Check". The three year exclusive agreement is subject to performance minimum purchase requirements. 36S is permitted to market the Company's products in Australia, Singapore, the United Arab Emirates and Oman. Under the terms of the distribution agreement 36S is expected to immediately begin marketing the company's tests to a large and varied customer base including hospitals, paramedic and emergency services, non-governmental organizations and military forces. 36S will focus on distribution of the company's rapid HIV, Hepatitis B, Malaria and Dengue Fever tests; as well as its rapid cholesterol test, Tri-Cholesterol "Check".
News For AKER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
07:12 EDTAKERRedChip Companies to hold a virtual conference
Subscribe for More Information
January 26, 2015
07:10 EDTAKERAkers Biosciences granted European patent for blood separator technology
Akers Biosciences announces that the European Patent Office has issued a patent surrounding the company's novel blood separator technology and method of separating a fluid fraction from whole blood. Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT and forms a key component of the company's PIFA product range. In addition to seraSTAT's incorporation within some of the company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use